MA42843A - Anticorps anti-cd115 - Google Patents
Anticorps anti-cd115Info
- Publication number
- MA42843A MA42843A MA042843A MA42843A MA42843A MA 42843 A MA42843 A MA 42843A MA 042843 A MA042843 A MA 042843A MA 42843 A MA42843 A MA 42843A MA 42843 A MA42843 A MA 42843A
- Authority
- MA
- Morocco
- Prior art keywords
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562219578P | 2015-09-16 | 2015-09-16 | |
| US201562220147P | 2015-09-17 | 2015-09-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA42843A true MA42843A (fr) | 2018-07-25 |
Family
ID=58289914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA042843A MA42843A (fr) | 2015-09-16 | 2016-09-16 | Anticorps anti-cd115 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10759861B2 (fr) |
| EP (1) | EP3349794A4 (fr) |
| KR (2) | KR102677543B1 (fr) |
| AU (2) | AU2016323582B2 (fr) |
| CA (1) | CA2998350A1 (fr) |
| HK (1) | HK1255056A1 (fr) |
| MA (1) | MA42843A (fr) |
| WO (1) | WO2017049038A2 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102677543B1 (ko) | 2015-09-16 | 2024-06-24 | 아블렉시스, 엘엘씨 | 항-cd115 항체 |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| WO2018222741A1 (fr) * | 2017-05-31 | 2018-12-06 | Oklahoma Medical Research Foundation | Anticorps bispécifiques pour le traitement de la pneumonie à streptocoques |
| WO2019105972A1 (fr) | 2017-11-30 | 2019-06-06 | Bayer Aktiengesellschaft | Antagonistes de l'ildr2 et associations correspondantes |
| EP3894014A4 (fr) * | 2018-12-13 | 2022-04-20 | Development Center for Biotechnology | Anticorps anti-csf-1r humain et ses utilisations |
| WO2021099944A1 (fr) | 2019-11-18 | 2021-05-27 | Janssen Biotech, Inc. | Récepteurs antigéniques chimériques anti-cd79, cellules car-t, et leurs utilisations |
| WO2021154530A1 (fr) * | 2020-01-27 | 2021-08-05 | Vanderbilt University | Anticorps humains anti-dengue et leurs procédés d'utilisation |
| WO2022235960A1 (fr) * | 2021-05-06 | 2022-11-10 | Sorrento Therapeutics, Inc. | Anticorps neutralisants qui se lient à des protéines de spicule du sars-cov-2 |
| WO2023039437A1 (fr) * | 2021-09-07 | 2023-03-16 | Mabloc, Llc | Compositions d'anticorps anti-sars-cov-2 et leurs utilisations |
| WO2023064435A2 (fr) * | 2021-10-15 | 2023-04-20 | The Children's Medical Center Corporation | Compositions et méthodes se rapportant à des anticorps neutralisant le sars-cov-2 |
| US20250332277A1 (en) * | 2024-04-26 | 2025-10-30 | Eli Lilly And Company | Protein tyrosine kinase 7 antibodies and antibody-drug conjugates |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2026147C (fr) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Agents cytotoxiques comprenant des maytansinoides et leur usage therapeutique |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| SI2311873T1 (sl) * | 2004-01-07 | 2018-12-31 | Novartis Vaccines And Diagnostics, Inc. | M-CSF-specifična monoklonska protitelesa in njihova uporaba |
| ZA200705695B (en) | 2004-12-21 | 2009-02-25 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
| PL2188313T3 (pl) | 2007-08-21 | 2018-04-30 | Amgen, Inc. | Białka wiążące ludzki antygen c-fms |
| US8470977B2 (en) | 2008-03-14 | 2013-06-25 | Transgene S.A. | Antibody against the CSF-1R |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| ES2722300T3 (es) * | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
| HRP20190047T1 (hr) * | 2010-05-04 | 2019-02-22 | Five Prime Therapeutics, Inc. | Protutijela koja se vežu na csf1r |
| TWI613215B (zh) * | 2012-02-22 | 2018-02-01 | 再生元醫藥公司 | 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途 |
| WO2014096333A1 (fr) * | 2012-12-20 | 2014-06-26 | Morphosys Ag | Anticorps anti-staphylocoques |
| KR102677543B1 (ko) | 2015-09-16 | 2024-06-24 | 아블렉시스, 엘엘씨 | 항-cd115 항체 |
-
2016
- 2016-09-16 KR KR1020187010459A patent/KR102677543B1/ko active Active
- 2016-09-16 KR KR1020247014651A patent/KR20240064051A/ko not_active Ceased
- 2016-09-16 EP EP16847356.9A patent/EP3349794A4/fr not_active Withdrawn
- 2016-09-16 HK HK18114180.1A patent/HK1255056A1/zh unknown
- 2016-09-16 US US15/760,322 patent/US10759861B2/en active Active
- 2016-09-16 MA MA042843A patent/MA42843A/fr unknown
- 2016-09-16 CA CA2998350A patent/CA2998350A1/fr active Pending
- 2016-09-16 WO PCT/US2016/052063 patent/WO2017049038A2/fr not_active Ceased
- 2016-09-16 AU AU2016323582A patent/AU2016323582B2/en not_active Ceased
-
2020
- 2020-06-16 US US16/902,940 patent/US11753478B2/en active Active
-
2022
- 2022-12-08 AU AU2022283715A patent/AU2022283715A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1255056A1 (zh) | 2019-08-02 |
| KR102677543B1 (ko) | 2024-06-24 |
| KR20180054701A (ko) | 2018-05-24 |
| US10759861B2 (en) | 2020-09-01 |
| EP3349794A4 (fr) | 2019-07-31 |
| EP3349794A2 (fr) | 2018-07-25 |
| WO2017049038A3 (fr) | 2017-04-27 |
| CA2998350A1 (fr) | 2017-03-23 |
| KR20240064051A (ko) | 2024-05-10 |
| US20180258175A1 (en) | 2018-09-13 |
| AU2016323582A1 (en) | 2018-04-19 |
| WO2017049038A2 (fr) | 2017-03-23 |
| AU2016323582B2 (en) | 2022-09-15 |
| US20200308291A1 (en) | 2020-10-01 |
| AU2022283715A1 (en) | 2023-02-02 |
| US11753478B2 (en) | 2023-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR21C1030I2 (fr) | Conjugué anticorps anti-her2-médicament | |
| EP3498840A4 (fr) | Anticorps anti-lag-3 | |
| MA49034A (fr) | Anticorps anti-lag3 | |
| EP3589313A4 (fr) | Anticorps anti-tigit | |
| EP3334757A4 (fr) | Anticorps anti-tigit | |
| EP3423089A4 (fr) | Anticorps anti-tigit | |
| EP3297671A4 (fr) | Anticorps anti-ror1 | |
| MA47268A (fr) | Anticorps anti-gpc3 | |
| MA45004A (fr) | Anticorps spécifiques anti-wt1-hla | |
| MA47472A (fr) | Anticorps | |
| EP3387442A4 (fr) | Anticorps anti-cd73 humanisés | |
| EP3334824A4 (fr) | Anticorps anti-pd-1 | |
| DK3344654T3 (da) | Anti-lag-3-antistoffer | |
| MA53297A (fr) | Anticorps anti-icos | |
| EP3319984C0 (fr) | Anticorps de liaison tau | |
| IL256099A (en) | Antibody | |
| DK3350218T5 (da) | Polyomavirus-neutraliserende antistoffer | |
| HUE060878T2 (hu) | Anti-transztiretin antitestek | |
| EP3492591A4 (fr) | Anticorps anti-b7-h4 | |
| DK3250593T3 (da) | Anti-transthyretin-antistoffer | |
| EP3319983C0 (fr) | Anticorps de liaison tau | |
| EP3526247A4 (fr) | Anticorps anti-il1-rap | |
| EP3484919A4 (fr) | Anticorps anti-bêta-amyloïde | |
| EP3617231A4 (fr) | Anticorps anti-gpc-1 | |
| EP3399992A4 (fr) | Anticorps autoréticulants |